GANX

Gain Therapeutics Inc

GANX, USA

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.

https://gaintherapeutics.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
GANX
stock
GANX

Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to Buy Nasdaq

Read more →
GANX
stock
GANX

Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Average Rating of “Moderate Buy” from Analysts Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$6.8

Analyst Picks

Strong Buy

3

Buy

4

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

24.52

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-89.42 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-48.16 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Low

0.86

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 11.65% of the total shares of Gain Therapeutics Inc

1.

JONES FINANCIAL COMPANIES LLLP

(1.8829%)

since

2025/06/30

2.

Vanguard Group Inc

(1.4864%)

since

2025/06/30

3.

Vanguard Institutional Extnd Mkt Idx Tr

(1.003%)

since

2025/07/31

4.

Geode Capital Management, LLC

(0.808%)

since

2025/06/30

5.

Marshall Wace Asset Management Ltd

(0.769%)

since

2025/06/30

6.

Gotham Asset Management, LLC

(0.684%)

since

2025/06/30

7.

CAMBRIDGE Invest RESEARCH ADVISORS, INC.

(0.4993%)

since

2025/06/30

8.

Citadel Advisors Llc

(0.4501%)

since

2025/06/30

9.

Fidelity Extended Market Index

(0.4249%)

since

2025/07/31

10.

BANOR SICAV Rosemary S EUR Acc

(0.3382%)

since

2025/06/30

11.

BlackRock Inc

(0.313%)

since

2025/06/30

12.

Northern Trust Corp

(0.2786%)

since

2025/06/30

13.

Renaissance Technologies Corp

(0.2615%)

since

2025/06/30

14.

Susquehanna International Group, LLP

(0.2213%)

since

2025/06/30

15.

Morgan Stanley - Brokerage Accounts

(0.2128%)

since

2025/06/30

16.

State Street Corp

(0.1979%)

since

2025/06/30

17.

iShares Micro-Cap ETF

(0.1755%)

since

2025/08/31

18.

Kovitz Investment Group Partners, LLC

(0.1324%)

since

2025/06/30

19.

Dauntless Investment Group, LLC

(0.128%)

since

2025/06/30

20.

Fidelity Total Market Index

(0.1254%)

since

2025/07/31

21.

Fidelity Series Total Market Index

(0.1073%)

since

2025/07/31

22.

Springbok Capital Management, LLC

(0.0996%)

since

2025/06/30

23.

Spartan Extended Market Index Pool F

(0.0994%)

since

2025/07/31

24.

Extended Equity Market Fund K

(0.0986%)

since

2025/06/30

25.

UBS Group AG

(0.0908%)

since

2025/06/30

26.

Bridgeway Capital Management, LLC

(0.0835%)

since

2025/06/30

27.

Bridgeway Ultra-Small Company Market

(0.0835%)

since

2025/06/30

28.

Northern Trust Extended Eq Market Idx

(0.082%)

since

2025/06/30

29.

NT Ext Equity Mkt Idx Fd - L

(0.082%)

since

2025/06/30

30.

NT Ext Equity Mkt Idx Fd - NL

(0.0683%)

since

2025/06/30

31.

Virtu Financial LLC

(0.0662%)

since

2025/06/30

32.

Benedict Financial Advisors, INC.

(0.0626%)

since

2025/06/30

33.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.053%)

since

2025/06/30

34.

Spartan Total Market Index Pool G

(0.0509%)

since

2025/07/31

35.

Fidelity Nasdaq Composite Index

(0.028%)

since

2025/07/31

36.

Vanguard U.S. Eq Idx ÂŁ Acc

(0.0265%)

since

2025/07/31

37.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0231%)

since

2025/06/30

38.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0195%)

since

2024/12/31

39.

1290 VT Micro Cap K

(0.0162%)

since

2025/07/31

40.

Extended Equity Market Fund M

(0.0124%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.15

EPS Estimate

-0.15

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(0.5)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(2)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.